Type 1 Diabetes Treatment Disappoints in Trial

But, Skyler added, "I personally don't think we should abandon GAD; I think we should think about the form it's in, and the route it's given."

Ludvigsson said further trials of GAD-alum are already on the way, using the drug as an intervention for people recently diagnosed with type 1 diabetes and as a preventive measure for people who have a high risk of developing type 1 diabetes.

More information

Learn more about type 1 diabetes from the American Diabetes Association.

Copyright © 2012 HealthDay. All rights reserved.

Reader Comments

Add Your Thoughts

Comment Name State Select One AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY International Email

Please enter the two words below into the text field underneath the image.

Incorrect please try again

Enter the words above: Enter the numbers you hear:

Your comment will be posted immediately, unless it is spam or contains profanity. For more information, please see our Comments FAQ.